Mark Emberton, MD, FRCS, presented “MRI-Based Prostate Cancer Screening in an Era of MCEDs” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
How to cite: Emberton, Mark. “MRI-Based Prostate Cancer Screening in an Era of MCEDs.” September 21, 2023. Accessed Nov 2024. https://grandroundsinurology.com/mri-based-prostate-cancer-screening-in-an-era-of-mceds/
MRI-Based Prostate Cancer Screening in an Era of MCEDs – Summary
Mark Emberton, MD, FRCS, discusses magnetic resonance imaging (MRI)-based prostate cancer screening in an era of multi-cancer early detection tests (MCEDs). Prof. Emberton explains that, while screening is beneficial, prostate cancer doesn’t lend itself to the MCED approach.
Prof. Emberton addresses high-quality imaging tools available for prostate cancer screening, mpMRI, and bi-parametric MRI. He outlines and illustrates possible approaches before enumerating challenges of previous screening trials, including poor adherence and contamination.
To combat these challenges, Prof. Emberton proposes a Zelen or embedded cohort design, calling it nondisruptive and fair, eliminating contamination, mitigating nonadherence, and permitting adjustments for underrepresented groups. Dr. Emberton summarizes that the demand for accurate prostate cancer screening and early detection is high.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Mark Emberton, MD, FRCS, is Professor of Interventional Oncology at the University College London. He is an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of The Charity Prostate Cancer UK. He was appointed Dean of UCL Faculty of Medical Sciences in 2015.
Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa). He specializes in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.
His research has been published in over 300 peer-reviewed scientific papers in journals including BMJ, Lancet Oncology and European Urology. He has also contributed to the development of guidelines for the management of PCa and lower urinary tract symptoms, published by the International Society of Geriatric Oncology and the European Association of Urology.
Professor Emberton is also involved in teaching within UCL and the London and South East Urological Training scheme. In addition to being a member of various urological and medical organisations (American Association of GenitoUrinary Surgeons, British Association of Urological Surgeons, European Association of Urology). He is a founding partner of London Urology Associates.
